Phase 2/3 Trial of Molnupiravir for Treatment of Covid-19 in Nonhospitalized Adults-Reference-Cited by-同舟云学术

Phase 2/3 Trial of Molnupiravir for Treatment of Covid-19 in Nonhospitalized Adults

Published:2022-01-25 Issue:2 Volume:1 Page:
ISSN:2766-5526
Container-title:NEJM Evidence
language:en
Short-container-title:NEJM Evidence

Author:

Caraco Yoseph¹,Crofoot Gordon E.²,Moncada Pablo Andres³,Galustyan Anna Nikolaevna⁴⁵,Musungaie Dany Badibanga⁶,Payne Brendan⁷,Kovalchuk Evgeniy⁸,Gonzalez Antonio⁹,Brown Michelle L.¹⁰,Williams-Diaz Angela¹⁰,Gao Wei¹⁰,Strizki Julie M.¹⁰,Grobler Jay¹⁰,Du Jiejun¹⁰,Assaid Christopher A.¹⁰,Paschke Amanda¹⁰,Butterton Joan R.¹⁰,Johnson Matthew G.¹⁰,De Anda Carisa¹⁰

Affiliation:

1. Clinical Pharmacology Unit, Hadassah-Hebrew University Medical Center, Jerusalem, Israel

2. Crofoot Research Center, Inc., Houston, TX

3. Department of Internal Medicine, Infectious Disease Service, Fundación Valle del Lili, Cali, Colombia

4. Saint Petersburg State Pediatric Medical University, Saint Petersburg, Russia

5. Strategic Medical System LLC, Saint Petersburg, Russia

6. Jongaie Research, Gauteng, South Africa

7. Departments of Infectious Diseases and Medical Virology, Newcastle upon Tyne Hospitals, Newcastle upon Tyne, UK

8. Medical Research Institute LLC, Saint Petersburg, Russia

9. Advanced Research for Health Improvement LLC, Immokalee, FL

10. Merck Research Laboratories, Merck & Co., Inc., Kenilworth, NJ

Publisher

Massachusetts Medical Society

Cited by 53 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Respiratory virus coinfections during the COVID-19 pandemic: epidemiologic analysis and clinical outcomes from the Phase 2/3 molnupiravir trial (MOVe-OUT);Microbiology Spectrum;2024-02

2. Virology and safety profile of Molnupiravir at three different doses for treatment of SARS‐CoV‐2: a systematic review and meta‐analysis;APMIS;2024-01-30

3. Strategies for the development and approval of COVID-19 vaccines and therapeutics in the post-pandemic period;Signal Transduction and Targeted Therapy;2023-12-21

4. Virologic Outcomes with Molnupiravir in Non-hospitalized Adult Patients with COVID-19 from the Randomized, Placebo-Controlled MOVe-OUT Trial;Infectious Diseases and Therapy;2023-11-23

5. Evaluation of oral small molecule drugs for the treatment of COVID-19 patients: a systematic review and network meta-analysis;Annals of Medicine;2023-11-15